HIGHLIGHTS
- who: Jingjie Chen from the Department of Radiotherapy and Chemotherapy, HwaMei Hospital, University of Chinese Academy of Sciences, Northwest Street, Haishu District, Ningbo, Zhejiang, China have published the Article: The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis, in the Journal: (JOURNAL)
- what: The authors focused on trial phases, tumor types, the number and characteristics of participants, the anti-tumor agents, dosage, and frequency of drug administration with a keen interest on the prognoses, specifically the ORR, CR, and PR.
- how: Durable responses and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.